Agonist News and Research

RSS

Penn researchers receive nearly $5 million to reduce opioid cravings

Opioid overdoses take the lives of tens of thousands of Americans annually. Two researchers from Penn State College of Medicine have received nearly $5 million from the National Institutes of Health to study whether an already-approved drug can be used to reduce cravings and prevent relapse in those struggling with opioid addiction.

9 Dec 2019

Drug used to treat Parkinson’s shows potential as a dementia treatment

Drug used to treat hallucinations and delusions in Parkinson's shows promise as treatment for dementia-related psychosis (DRP).

5 Dec 2019

New targeted treatment for insomnia has fewer side effects

Insomnia is one of the most common sleep disorders, and is most commonly treated with hypnotics. However, hypnotics have motor and cognitive side effects.

22 Nov 2019

Effective non-surgical treatment options for urinary incontinence

A common myth about urinary incontinence (the loss of bladder control or urinary leakage) in women is that surgery is your only option.

10 Nov 2019

Botanical product kratom may cause liver toxicity and injury, study finds

Data from a new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases – found that kratom, a popular and widely available product, may cause liver toxicity and severe liver injury.

10 Nov 2019

GLP-1 receptors could serve as targets for novel medications to treat opioid use disorder

Opioid use disorder and overdose deaths are a major public health crisis in the United States. While medication-assisted treatments for opioid use disorder exist, these treatments remain inadequate for many patients, resulting in a high rate of relapse following detoxification.

31 Oct 2019

Research forum to present results of novel anti-obesity medications

Rhythm Pharmaceuticals and Novartis will present findings from the latest stages of clinical evaluation of new anti-obesity medications during a special late-breaking research forum titled "Emerging Pharmacological Anti-obesity Therapies."

31 Oct 2019

DGIST and Ahn-Gook Pharmaceutical sign R&D agreement for development of anti-cancer antibody

A research group, led by Professor Kyungmoo Yea at the Department of New Biology, DGIST has signed an agreement on the joint R&D for the development of anti-cancer antibody with Ahn-Gook Pharmaceutical Co., Ltd. in September.

30 Oct 2019

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.

30 Oct 2019

Researchers are confronting opioid epidemic in multiple ways

With opioid drug overdose deaths skyrocketing in recent decades, researchers at Brown University's School of Public Health are confronting the epidemic in multiple ways.

30 Oct 2019

Study explores distribution of new diabetes cases and specialist density in the U.S.

In the last five years, the landscape of type 2 diabetes treatment has changed dramatically. Two new classes of drugs -- SGLT2 inhibitors and GLP-1 receptor agonists -- have been shown to prevent some of the most serious diabetes complications, including heart and kidney conditions, in patients.

25 Oct 2019

Study reveals novel druggable driver gene in human gastrointestinal stromal tumors

Sarcomas - cancers that arise from transformed mesenchymal cells (a type of connective tissue) - are quite deadly. Gastrointestinal stromal tumors are the most common human sarcoma and are initiated by activating mutations in the KIT receptor tyrosine kinase.

24 Oct 2019

Naloxone distribution increases rapidly after availability of kits at Ontario pharmacies

The distribution of naloxone kits in Ontario increased rapidly after they were made available free of charge through community pharmacies and reached almost 68,000 people in a two-year period, according to a study led by researchers at St. Michael's Hospital of Unity Health Toronto and ICES.

18 Oct 2019

Research finds drugs for better long-term treatment of poorly controlled asthma

The waning effectiveness of drugs over time continues to be a major challenge in treating diseases, including asthma.

11 Oct 2019

Triple-drug combo inhaler for asthmatics with poor symptom control

New research shows that asthmatics who have poor symptom control could be benefited by using a three-drug combination inhaler. The standard treatment for these patients is a two-drug combination of an inhaled corticosteroid (ICS) and a long acting beta 2 agonist (LABA). The third ingredient added to the mix is a long acting muscarinic antagonist, add the researchers. This combination successfully improved lung function and reduced exacerbations of asthma wrote the researchers.

1 Oct 2019

African American children respond differently to step-up therapies for asthma

African Americans suffer asthma more often and more severely than Caucasian patients. However, clinical trials that have shaped treatment guidelines have included few African Americans.

27 Sep 2019

Lifelong choline supplementation holds potential to prevent Alzheimer's disease

In a new study, Biodesign researchers reveal that a lifelong dietary regimen of choline holds the potential to prevent Alzheimer's disease.

27 Sep 2019

Mystery underlying cardiac toxicity caused by diabetes drugs solved

Like catching two fish with one worm, treating two problems with a single drug is efficient, but exceedingly difficult.

25 Sep 2019

Wistar awarded more than $12 million to study opioid use in HIV-infected people

The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse, part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar's HIV Research Program.

24 Sep 2019

Prilenia's lead compound selected to participate in first-ever ALS platform trial

Prilenia, a newly formed biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that Pridopidine, its lead compound, has been selected as the first of three potential new treatments to be included in the launch of the first ever platform trial in amyotrophic lateral sclerosis (ALS).

19 Sep 2019